Results 21 to 30 of about 2,175,372 (155)

Targeting the MIR4435-2HG/miR-29c-3p/FSP1 axis overcomes lenvatinib resistance by inducing ferroptosis in hepatocellular carcinoma [PDF]

Cancer Cell International
Background Lenvatinib resistance is a major clinical challenge in advanced hepatocellular carcinoma (HCC). While ferroptosis has emerged as a promising target to overcome therapy resistance, the mechanistic link between ferroptosis and lenvatinib ...
Congyue Zhang, Mengjiao Sun, Yue Shi, Jiawei Cui, Yaoyao Mao, Zhandong Lin, Xiaoqing Wu, Shaoya Li, Yuemin Nan   +8 more
doaj   +2 more sources

Hypoxia-induced endoplasmic reticulum stress mediates lenvatinib resistance in hepatocellular carcinoma through the IRE1α-XBP1s-HIF1α pathway [PDF]

Journal of Cancer Research and Clinical Oncology
Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths globally, with a dismal prognosis for advanced patients.
Chong Zhang, Yuxin Jiang, Jiatao Liu, Guoping Sun, Hanqing Yu   +4 more
doaj   +2 more sources

A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance

Acta Pharmaceutica Sinica B, 2023
Lenvatinib, a second-generation multi-receptor tyrosine kinase inhibitor approved by the FDA for first-line treatment of advanced liver cancer, facing limitations due to drug resistance.
Lei Sun, Arabella H. Wan, Shijia Yan, Ruonian Liu, Jiarui Li, Zhuolong Zhou, Ruirui Wu, Dongshi Chen, Xianzhang Bu, Jingxing Ou, Kai Li, Xiongbin Lu, Guohui Wan, Zunfu Ke   +13 more
doaj   +2 more sources

Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma [PDF]

Frontiers in Immunology, 2023
Anti-PD-1 immunotherapy has been extensively used in treatment of patients with advanced metastatic renal cell carcinoma (mRCC). Several prospective clinical trials showed that the combined treatment of anti-PD-1 antibody plus lenvatinib, a potent ...
Tingting Tan, Tingting Tan, Xiaotong Lin, Xiaotong Lin, Jing Ling, Jing Ling, Rong Wang, Yue Chen, Longmei Cai, Jingyuan Sun, Dehua Wu, Dehua Wu, Guozhu Xie, Guozhu Xie   +13 more
doaj   +2 more sources

Aurora-A promotes lenvatinib resistance experimentally through hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma [PDF]

International Journal of Immunopathology and Pharmacology
Objective: This study aimed to investigate whether the dysregulation of Aurora-A is involved in lenvatinib resistance in hepatocellular carcinoma. Methods: Bioinformatics tools and drug sensitivity assays were used to investigate the association between ...
Mubalake Abudoureyimu, Ni Sun, Weiwei Chen, Xinrong Lin, Fan Pan, Rui Wang   +5 more
doaj   +2 more sources

Targeting CREB3L2-mediated lipid metabolism overcomes lenvatinib resistance and attenuates the progression of hepatocellular carcinoma [PDF]

Cell Death and Disease
When hepatocellular carcinoma (HCC) cells exhibit malignant biological behaviors, lipid metabolic reprogramming occurs concomitantly. Thus, identifying regulators of metabolic reprogramming offers new potential targets for therapy.
Shiguang Yang, Shaoqing Liu, Jie Li, Shengwei Mao, Qifeng Yu, Xuhui Zhao, Xiaoling Wu, Jiafeng Chen, Yichao Bu, Weiren Liu, Yuan Fang, Yinghong Shi   +11 more
doaj   +2 more sources

CLDN4 palmitoylation promotes hepatic-to-biliary lineage transition and lenvatinib resistance in hepatocellular carcinoma [PDF]

Cell Reports Medicine
Summary: Hepatocellular carcinoma (HCC) exhibits significant plasticity, enabling phenotypic switching that promotes a drug-tolerant state and circumvents drug-induced cytotoxicity.
Minghao Xu, Yimin Zheng, Junbo Chen, Chao Gao, Miao Zhu, Aying Ma, Bugang Liang, Wenxin Xu, Jia Fan, Haibo Zhou, Aiwu Ke, Yinghao Shen   +11 more
doaj   +2 more sources

Lactylation‐Driven IGF2BP3‐Mediated Serine Metabolism Reprogramming and RNA m6A—Modification Promotes Lenvatinib Resistance in HCC [PDF]

Advanced Science
Acquired resistance remains a bottleneck for molecular‐targeted therapy in advanced hepatocellular carcinoma (HCC). Metabolic adaptation and epigenetic remodeling are recognized as hallmarks of cancer that may contribute to acquired resistance.
Yuanxiang Lu, Jinghan Zhu, Yuxin Zhang, Wentao Li, Yixiao Xiong, Yunhui Fan, Yang Wu, Jianping Zhao, Changzhen Shang, Huifang Liang, Wanguang Zhang   +10 more
doaj   +2 more sources

Calpain 2 promotes Lenvatinib resistance and cancer stem cell traits via both proteolysis-dependent and independent approach in hepatocellular carcinoma [PDF]

Molecular Biomedicine
Lenvatinib, an approved first-line regimen, has been widely applied in hepatocellular carcinoma (HCC). However, clinical response towards Lenvatinib was limited, emphasizing the importance of understanding the underlying mechanism of its resistance ...
Xiaolu Ma, Kaixia Zhou, Tianqing Yan, Ling Hu, Suhong Xie, Hui Zheng, Ying Tong, Heng Zhang, Yanchun Wang, Zhiyun Gong, Cuncun Chen, Yanan Tian, Lin Guo, Renquan Lu   +13 more
doaj   +2 more sources

Impact of Type of Lenvatinib Resistance on Prognosis and Second-Line Regimen in Patients with Virus-Associated HCC [PDF]

Journal of Hepatocellular Carcinoma
Yijie Zhang,1,2,* Jin Lei,3,* Huaxing Ma,3 Shi Zuo2 1Department of General Surgery, Medical College of Soochow University, Suzhou, People’s Republic of China; 2Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical ...
Zhang Y, Lei J, Ma H, Zuo S
doaj   +2 more sources